Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Published in The New England Journal of Medicine on May 11, 2025, this phase 3b, open-label, randomized trial compares the efficacy and safety of tirzepatide (10 or 15 mg once weekly) with semaglutide (1.7 or 2.4 mg once weekly) for weight loss in adults with obesity but without type 2 diabetes. Conducted across 47 sites […]